JP2013515486A5 - - Google Patents

Download PDF

Info

Publication number
JP2013515486A5
JP2013515486A5 JP2012546229A JP2012546229A JP2013515486A5 JP 2013515486 A5 JP2013515486 A5 JP 2013515486A5 JP 2012546229 A JP2012546229 A JP 2012546229A JP 2012546229 A JP2012546229 A JP 2012546229A JP 2013515486 A5 JP2013515486 A5 JP 2013515486A5
Authority
JP
Japan
Prior art keywords
antigen
antibody
binding fragment
ser
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012546229A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013515486A (ja
JP6000855B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/061987 external-priority patent/WO2011079257A2/en
Publication of JP2013515486A publication Critical patent/JP2013515486A/ja
Publication of JP2013515486A5 publication Critical patent/JP2013515486A5/ja
Application granted granted Critical
Publication of JP6000855B2 publication Critical patent/JP6000855B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012546229A 2009-12-24 2010-12-23 ヒトアンギオポエチン様タンパク質４に対するヒト抗体 Expired - Fee Related JP6000855B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US29009209P 2009-12-24 2009-12-24
US61/290,092 2009-12-24
US30635910P 2010-02-19 2010-02-19
US61/306,359 2010-02-19
US32831610P 2010-04-27 2010-04-27
US61/328,316 2010-04-27
US34927310P 2010-05-28 2010-05-28
US61/349,273 2010-05-28
US35612610P 2010-06-18 2010-06-18
US61/356,126 2010-06-18
PCT/US2010/061987 WO2011079257A2 (en) 2009-12-24 2010-12-23 Human antibodies to human angiopoietin-like protein 4

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015096446A Division JP2015145424A (ja) 2009-12-24 2015-05-11 ヒトアンギオポエチン様タンパク質４に対するヒト抗体

Publications (3)

Publication Number Publication Date
JP2013515486A JP2013515486A (ja) 2013-05-09
JP2013515486A5 true JP2013515486A5 (enExample) 2014-02-06
JP6000855B2 JP6000855B2 (ja) 2016-10-05

Family

ID=43629324

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012546229A Expired - Fee Related JP6000855B2 (ja) 2009-12-24 2010-12-23 ヒトアンギオポエチン様タンパク質４に対するヒト抗体
JP2015096446A Pending JP2015145424A (ja) 2009-12-24 2015-05-11 ヒトアンギオポエチン様タンパク質４に対するヒト抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015096446A Pending JP2015145424A (ja) 2009-12-24 2015-05-11 ヒトアンギオポエチン様タンパク質４に対するヒト抗体

Country Status (30)

Country Link
US (2) US8354103B2 (enExample)
EP (1) EP2516466B1 (enExample)
JP (2) JP6000855B2 (enExample)
KR (1) KR101842570B1 (enExample)
CN (1) CN102741284A (enExample)
AR (1) AR079708A1 (enExample)
AU (1) AU2010336369C1 (enExample)
BR (1) BR112012017765A2 (enExample)
CA (1) CA2785158C (enExample)
CY (1) CY1118898T1 (enExample)
DK (1) DK2516466T3 (enExample)
ES (1) ES2628135T3 (enExample)
HR (1) HRP20170524T1 (enExample)
HU (1) HUE034722T2 (enExample)
IL (1) IL220402A (enExample)
JO (1) JO3274B1 (enExample)
LT (1) LT2516466T (enExample)
MX (1) MX337082B (enExample)
NZ (1) NZ600768A (enExample)
PL (1) PL2516466T3 (enExample)
PT (1) PT2516466T (enExample)
RS (1) RS56009B1 (enExample)
RU (1) RU2580045C2 (enExample)
SG (1) SG181784A1 (enExample)
SI (1) SI2516466T1 (enExample)
SM (1) SMT201700280T1 (enExample)
TW (1) TWI488643B (enExample)
UY (1) UY33144A (enExample)
WO (1) WO2011079257A2 (enExample)
ZA (1) ZA201204507B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
WO2012101253A1 (en) 2011-01-28 2012-08-02 Sanofi Pharmaceutical compositions comprising human antibodies to pcsk9
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
BR112014006394A2 (pt) * 2011-09-19 2017-03-28 Kymab Ltd manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
US20150071941A1 (en) * 2012-04-13 2015-03-12 The Johns Hopkins University Treatment of ischemic retinopathies
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
TWI596115B (zh) 2012-08-13 2017-08-21 再生元醫藥公司 具有ｐＨ－依賴性結合特性之抗－ＰＣＳＫ９抗體
GB201301313D0 (en) * 2013-01-25 2013-03-06 Univ Singapore Respiratory Tract Infections
MX2015016978A (es) 2013-06-10 2016-04-25 Merck Sharp & Dohme Proteinas de union a antigeno neutralizantes de citomegalovirus.
KR101538787B1 (ko) * 2013-06-27 2015-07-22 인하대학교 산학협력단 췌장염 진단용 바이오 마커 조성물
US11293929B2 (en) * 2014-01-07 2022-04-05 Bioatla, Inc. Proteins targeting orthologs
US9771417B2 (en) * 2014-08-07 2017-09-26 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
US9988443B2 (en) 2014-08-07 2018-06-05 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
US9556225B2 (en) * 2014-10-15 2017-01-31 Uniao Quimica Farmaceutica Nacional S/A Peptide stimulator of cell survival and proliferation
US20180125816A1 (en) 2015-05-11 2018-05-10 Cadila Healthcare Limited Saroglitazar magnesium for the treatment of chylomicronemia syndrome
WO2017011929A1 (zh) * 2015-07-17 2017-01-26 北京大学第一医院 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
CN107922507B (zh) 2015-08-18 2022-04-05 瑞泽恩制药公司 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
WO2018094112A1 (en) 2016-11-17 2018-05-24 Regeneron Pharmaceuticals, Inc. Methods of treating obesity with anti-angptl8 antibodies
EP3565598A4 (en) 2017-01-03 2020-10-28 Trellis Bioscience, LLC NATIVE HUMAN ANTIBODIES FOR TIM-3 AND B7-H3 IMMUNE CHECKPOINT MODULATION TARGETS
US20190031774A1 (en) 2017-06-09 2019-01-31 Sanofi Biotechnology Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
CN114008079A (zh) * 2019-03-20 2022-02-01 贾夫林肿瘤学公司 抗adam12抗体和嵌合抗原受体以及包含其的组合物和方法
AU2020339478A1 (en) 2019-08-29 2021-05-06 Remegen Co., Ltd. Anti PD-L1 antibody and use thereof
KR20220112290A (ko) * 2019-12-09 2022-08-10 엠피리코 인크. 안지오포이에틴 유사 4(angptl4) 관련 질환의 치료를 위한 올리고뉴클레오타이드
MA56074B1 (fr) 2020-02-26 2023-11-30 Vir Biotechnology Inc Anticorps contre le sars-cov-2
JP2023533253A (ja) * 2020-07-02 2023-08-02 マブリティクス， インコーポレイテッド 細胞結合タンパク質および使用の方法
WO2022006555A2 (en) * 2020-07-02 2022-01-06 Gigagen, Inc. BISPECIFIC ANTIGEN BINDING PROTEINS TARGETING PD-L1 AND TGF-β AND METHODS OF USE
CN119343148A (zh) * 2022-06-10 2025-01-21 南洋理工大学 使用angptl4拮抗剂治疗肝纤维化、炎症或相关疾病的方法
IL318578A (en) * 2022-08-02 2025-03-01 Nona Biosciences Suzhou Co Ltd Msln antibody-drug conjugate
CN117535353A (zh) * 2023-10-11 2024-02-09 首都医科大学附属北京潞河医院 一种糖尿病视网膜病变模型的建立方法及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
BRPI0519596B1 (pt) * 2004-12-21 2022-01-18 Astrazeneca Ab Agente de ligação alvejado, anticorpo monoclonal que se liga a angiopoietina-2, molécula de ácido nucleico, vetor, e, uso do agente de ligação alvejado
EA016185B1 (ru) * 2005-01-07 2012-03-30 Лексикон Фармасьютикалз, Инк. Моноклональное антитело или его фрагмент к подобному ангиопоэтину белку 4 (angptl4) и их применение
JP5489465B2 (ja) 2005-12-16 2014-05-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｄｌｌ４アンタゴニストによって腫瘍増殖を阻害する治療方法
AU2007227251A1 (en) 2006-03-20 2007-09-27 Amgen Fremont, Inc. Antibodies directed to angiopoietin-like protein 4 and uses thereof
SI2374818T1 (sl) 2006-06-02 2013-03-29 Regeneron Pharmaceuticals, Inc. Visokoafinitetna protitelesa za humani IL-6 receptor
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).

Similar Documents

Publication Publication Date Title
JP2013515486A5 (enExample)
RU2012131547A (ru) Антитела человека против ангиопоэтин-подобного белка 4 человека
US11542325B2 (en) Anti-activin A antibodies and uses thereof
RU2013155906A (ru) Антитела анти-angptl3 и их применение
CA2698382C (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin
US20160032014A1 (en) Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
RU2012156938A (ru) Антитела против gdf8 человека
RU2014147773A (ru) Человеческие антитела с высокой аффинностью к рецепторам il-4 человека
RU2011129316A (ru) Высокоаффинные человеческие антитела к pcsk9
JP2013542194A5 (enExample)
JP7292526B2 (ja) 操作された抗ｉｌ－２抗体
JP2018510617A5 (enExample)
JP2016501892A5 (enExample)
RU2019139093A (ru) Фармацевтическая композиция на основе антитела к pd-l1 и ее применение
RU2016122340A (ru) Il-17a-связующий агент и способы его применения
JP6949012B2 (ja) Ｂ型肝炎表面抗原に対する抗体及びその使用
EP2766394A1 (en) Treatment for rheumatoid arthritis
JP2019162119A5 (enExample)
CN111094339A (zh) 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
WO2014072741A1 (en) Humanised antibody and method of production thereof
CA2824313A1 (en) Tlr3 binding agents
EP4253424A1 (en) Bispecific antibody and use thereof
CN111808196B (zh) 抗pd-1抗体及其用途
WO2018080914A1 (en) Anti-rankl antibodies and uses thereof
WO2021063331A1 (zh) EZH2抑制剂与含有TGF-β受体的融合蛋白联合在制备治疗肿瘤的药物中的用途